Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors

A Phase I Study of Escalating Doses of CPT-11 and 5fluorouracil (5FU) Plus PN401 With a Fixed Dose of Leucovorin in Patients With Solid Tumor Malignancies.

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00044785

Enrollment

Registered

2002-09-06

Start date

2002-08-31

Completion date

2004-03-31

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Keywords

colorectal cancer, gastric cancer, breast cancer

Brief summary

CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential. It is hypothesized that adding PN401 to the CPT-11, 5FU, leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well tolerated and therefore potentially increase effectiveness.

Interventions

DRUGtriacetyluridine

DRUGfluorouracil

DRUGleucovorin

DRUGcamptosar

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must be at least 18 years of age; * Life expectancy: At least 3 months; * Performance status: ECOG of 0 or 1; * Histologic or cytologic proof of a solid tumor cancer that is not amenable to curative surgical resection; * Evaluable or measurable disease documented within 4 weeks of the start of treatment; * Prior chemotherapy or radiotherapy is allowed if 4 weeks or more have elapsed prior to starting treatment and patients have recovered from toxicities of prior treatment; * Adequate organ function: Hematopoietic: ANC = 1500/ul or more, Platelets = 100,000/ul or more, Hemoglobin = 9.5 g/dL or more, transfusion prior to evaluation is allowed; Hepatic: Bilirubin = 2.0 mg/dL or less and SGPT(ALT) and SGOT(AST) \< 3 x upper limit of normal (\< 5 x upper limit of normal if liver metastases present) Renal: Serum Creatinine \< 2.0 mg/dL; * Patient has the initiative, geographic proximity, and means to be compliant with the protocol; * Fertile patients (male or female) must agree to use effective contraception; * Must be able to swallow and retain tablets.

Exclusion criteria

* Major surgery within the four weeks preceding the start of treatment; * Serious medical or psychiatric illness that would prevent self-determined informed consent; * Intensive chemotherapy treatment; * Infection or antibiotics at the time of screening; * Uncontrolled cardiovascular, pulmonary, renal, neurologic, psychiatric, or hepatic dysfunction; * Pregnant or nursing; * Pre-existing diarrhea or uncontrolled clinically significant illness other than cancer (i.e. ulcerative colitis, malabsorption syndrome); * Brain metastases that have not been stable for more than 3 months; * Known Dihydropyrimidine Dehydrogenase (DPD) deficiency.

Design outcomes

Primary

Measure	Time frame
Safety and Maximum Tolerated Dose	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026